Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence in Tamil Nadu through India’s two COVID waves: Evidence on antibody decline following infection and vaccination

T.S. Selvavinayagam, A. Somasundaram, Jerard Maria Selvam, Sabareesh Ramachandran, P. Sampath, V. Vijayalakshmi, C. Ajith Brabhu Kumar, Sudharshini Subramaniam, S Raju, R Avudaiselvi, V. Prakash, N. Yogananth, Gurunathan Subramanian, A Roshini, D.N. Dhiliban, Sofia Imad, Vaidehi Tandel, Rajeswari Parasa, Stuti Sachdeva, View ORCID ProfileAnup Malani
doi: https://doi.org/10.1101/2021.11.14.21265758
T.S. Selvavinayagam
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Somasundaram
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerard Maria Selvam
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabareesh Ramachandran
2University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Sampath
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Vijayalakshmi
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Ajith Brabhu Kumar
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudharshini Subramaniam
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Raju
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Avudaiselvi
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Prakash
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Yogananth
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gurunathan Subramanian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Roshini
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.N. Dhiliban
1Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Imad
3IDFC Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vaidehi Tandel
4independent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajeswari Parasa
3IDFC Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuti Sachdeva
4independent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anup Malani
4independent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anup Malani
  • For correspondence: amalani@uchicago.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Three rounds of population-representative serological studies through India’s two COVID waves (round 1, 19 October-30 November 2020; round 2, 7-30 April 2021; and round 3, 28 June-7 July7, 2021) were conducted at the district-level in Tamil Nadu state (population 72 million). State-level seroprevalence in rounds 1, 2 and 3 were 31.5%, 22.9%, and 67.1%. Estimated seroprevalence implies that at least 22.6 and 48.1 million persons were infected by the 30 November 2020 and 7 July 2021. There was substantial variation across districts in the state in each round. Seroprevalence ranged from 11.1 to 49.8% (round 1), 7.9 to 50.3% (round 2), and 37.8 to 84% (round 3). Seroprevalence in urban areas was higher than in rural areas (35.7 v. 25.7% in round 1, 74.8% v. 64.1% in round 3). Females had similar seroprevalence to males (30.8 v. 30.2% in round 1, 67.5 v. 65.5% in round 3). While working age populations (age 40-49: 31.6%) had significantly higher seroprevalence than the youth (age 18-29: 30.4%) or elderly (age 70+: 26.5%) in round 1, only the gap between working age (age 40-49: 66.7%) and elderly (age 70+: 59.6%) remained significant in round 3. Seroprevalence was greater among those who were vaccinated for COVID (25.7% v. 20.9% in round 2, 80.0% v. 62.3% in round 3). While the decline in seroprevalence from round 1 to 2 suggests antibody decline after natural infection, we do not find significant decline in antibodies among those receiving at least 1 dose of vaccine between rounds 2 and 3.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Government of Tamil Nadu.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu, and the Institutional Ethics Committee of Madras Medical College, Chennai, India, gave ethical approval of this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

These data are not publically available. However, researchers may approach the Government of Tamil Nadu to request access. The decision to grant access will be made by the government.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 15, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence in Tamil Nadu through India’s two COVID waves: Evidence on antibody decline following infection and vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence in Tamil Nadu through India’s two COVID waves: Evidence on antibody decline following infection and vaccination
T.S. Selvavinayagam, A. Somasundaram, Jerard Maria Selvam, Sabareesh Ramachandran, P. Sampath, V. Vijayalakshmi, C. Ajith Brabhu Kumar, Sudharshini Subramaniam, S Raju, R Avudaiselvi, V. Prakash, N. Yogananth, Gurunathan Subramanian, A Roshini, D.N. Dhiliban, Sofia Imad, Vaidehi Tandel, Rajeswari Parasa, Stuti Sachdeva, Anup Malani
medRxiv 2021.11.14.21265758; doi: https://doi.org/10.1101/2021.11.14.21265758
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Seroprevalence in Tamil Nadu through India’s two COVID waves: Evidence on antibody decline following infection and vaccination
T.S. Selvavinayagam, A. Somasundaram, Jerard Maria Selvam, Sabareesh Ramachandran, P. Sampath, V. Vijayalakshmi, C. Ajith Brabhu Kumar, Sudharshini Subramaniam, S Raju, R Avudaiselvi, V. Prakash, N. Yogananth, Gurunathan Subramanian, A Roshini, D.N. Dhiliban, Sofia Imad, Vaidehi Tandel, Rajeswari Parasa, Stuti Sachdeva, Anup Malani
medRxiv 2021.11.14.21265758; doi: https://doi.org/10.1101/2021.11.14.21265758

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8566)
  • Forensic Medicine (4)
  • Gastroenterology (385)
  • Genetic and Genomic Medicine (1755)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1245)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (376)
  • Infectious Diseases (except HIV/AIDS) (10306)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1679)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1772)
  • Public and Global Health (3845)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)